13 May, 2024May Health raises $25 million in Series B funding to advance development for Ovarian Rebalancing therapy
6 May, 2024Mediar advances first-in-class fibrosis portfolio to the clinic with first cohort dosing in Phase 1 trial of MTX-463 and establishes clinical advisory board
6 May, 2024Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib
2 May, 2024Amolyt Pharma Granted FDA Fast Track Designation for Eneboparatide for the Treatment of Hypoparathyroidism